1,906 Shares in Elevance Health, Inc. $ELV Acquired by MBL Wealth LLC

MBL Wealth LLC purchased a new position in Elevance Health, Inc. (NYSE:ELV) in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 1,906 shares of the company’s stock, valued at approximately $741,000.

Several other large investors have also added to or reduced their stakes in ELV. Strategic Planning Group LLC bought a new stake in shares of Elevance Health during the 3rd quarter valued at $326,000. Brookstone Capital Management grew its position in shares of Elevance Health by 1.2% in the 3rd quarter. Brookstone Capital Management now owns 3,886 shares of the company’s stock worth $1,511,000 after buying an additional 46 shares during the period. Root Financial Partners LLC purchased a new stake in shares of Elevance Health in the 3rd quarter worth about $275,000. Pinnacle Bancorp Inc. increased its stake in shares of Elevance Health by 26.2% in the 3rd quarter. Pinnacle Bancorp Inc. now owns 164 shares of the company’s stock worth $64,000 after acquiring an additional 34 shares in the last quarter. Finally, Vest Financial LLC increased its stake in shares of Elevance Health by 7.5% in the 3rd quarter. Vest Financial LLC now owns 60,888 shares of the company’s stock worth $23,674,000 after acquiring an additional 4,261 shares in the last quarter. Institutional investors own 89.24% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on the company. Guggenheim lifted their price objective on Elevance Health from $460.00 to $485.00 and gave the company a “buy” rating in a research note on Thursday. Royal Bank Of Canada boosted their target price on shares of Elevance Health from $424.00 to $455.00 and gave the company a “sector perform” rating in a research note on Thursday. Robert W. Baird increased their target price on Elevance Health from $393.00 to $406.00 and gave the company a “neutral” rating in a report on Thursday. Weiss Ratings reissued a “hold (c)” rating on shares of Elevance Health in a research report on Thursday, August 13th. Finally, Barclays raised their target price on Elevance Health from $469.00 to $472.00 and gave the stock an “overweight” rating in a research report on Thursday. Fifteen equities research analysts have rated the stock with a Buy rating and eight have given a Hold rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $455.57.

Insider Buying and Selling at Elevance Health

In related news, CFO Mark Kaye sold 10,584 shares of the company’s stock in a transaction on Thursday, October 22nd. The shares were sold at an average price of $440.13, for a total transaction of $4,658,335.92. Following the completion of the transaction, the chief financial officer owned 19,919 shares in the company, valued at approximately $8,766,949.47. This represents a 34.70% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.34% of the stock is currently owned by company insiders.

Key Elevance Health News

Here are the key news stories impacting Elevance Health this week:

• Positive Sentiment: Third-quarter adjusted earnings per share rose 15.9% and exceeded consensus, while revenue also topped expectations. Elevance raised its 2026 adjusted EPS outlook to at least $29, citing disciplined cost management and improved medical-cost trends. Elevance Health Q3 Results
• Positive Sentiment: Carelon’s expansion and clinical programs remain growth drivers; its cancer program reportedly reduced avoidable inpatient admissions by 15%. Management also highlighted actions intended to improve Medicaid profitability. ELV Q3 Deep Dive
• Positive Sentiment: TD Cowen raised its price target to $495 from $465 and maintained a Buy rating, indicating continued confidence in the earnings recovery. TD Cowen Rating
• Positive Sentiment: Elevance declared a quarterly dividend of $1.72 per share, supporting its shareholder-return profile. Elevance Health Dividend
• Neutral Sentiment: Elevance appointed Jeff Park as president of Carelon in a services leadership shift. The move may support execution, but its financial impact is not yet clear. Carelon Leadership Shift
• Neutral Sentiment: Morgan Stanley lifted its target to $449 from $404 but retained an Equal Weight rating, suggesting limited upside after the recent advance. Morgan Stanley Rating
• Negative Sentiment: Officer Mark B. Kaye disclosed an intent to sell 10,584 shares valued at approximately $4.66 million. While the sale may be routine, it can weigh on sentiment near a 52-week high. Officer Share Sale
• Negative Sentiment: Analysts continue to flag sustainability risks: nine-month operating gain declined, and Medicaid margins remain under pressure. Robert W. Baird kept a Neutral rating with a $406 target, below the current trading level. Elevance Health Earnings Analysis

Elevance Health Stock Performance

NYSE:ELV traded down $5.23 during mid-day trading on Friday, hitting $440.05. 1,173,816 shares of the company traded hands, compared to its average volume of 1,329,873. The company has a quick ratio of 1.52, a current ratio of 1.47 and a debt-to-equity ratio of 0.68. The stock’s fifty day moving average price is $408.32 and its 200-day moving average price is $390.89. The firm has a market cap of $95.43 billion, a price-to-earnings ratio of 18.77, a price-to-earnings-growth ratio of 2.32 and a beta of 0.70. Elevance Health, Inc. has a one year low of $274.84 and a one year high of $450.69.

Elevance Health (NYSE:ELV) last announced its quarterly earnings data on Wednesday, October 21st. The company reported $6.99 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $4.71 by $2.28. The company had revenue of $50.44 billion during the quarter, compared to the consensus estimate of $49.28 billion. Elevance Health had a return on equity of 14.97% and a net margin of 2.55%. The firm’s revenue was up .7% on a year-over-year basis. During the same period in the previous year, the company posted $6.03 EPS. Research analysts anticipate that Elevance Health, Inc. will post 27.09 earnings per share for the current fiscal year.

Elevance Health Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, December 18th. Stockholders of record on Friday, December 4th will be given a $1.72 dividend. This represents a $6.88 annualized dividend and a dividend yield of 1.6%. The ex-dividend date is Friday, December 4th. Elevance Health’s payout ratio is presently 29.34%.

Elevance Health Company Profile

Elevance Health, Inc (NYSE: ELV) is a diversified health benefits company that provides health insurance and related services in the United States. Its offerings serve employers, individuals and families, as well as members of government-sponsored programs, including Medicare and Medicaid. The company provides medical, pharmacy, behavioral health and other benefits through a range of health plans and specialty products.

Elevance Health operates its health benefits businesses through a portfolio that includes Blue Cross and Blue Shield-affiliated plans and other insurance offerings.